Results from first comparative study with the Episealer® Knee implant accepted for publication

Episurf Medical (Nasdaq: EPIS B) today announces that a manuscript with results from a study with the title Patient specific resurfacing implant knee surgery in subjects with early osteoarthritis results in medial pivot and lateral femoral rollback during flexion: a retrospective pilot study by P. Moewis, R. Kaiser, A. Trepczynski, C. von Tycowicz, L. Krahl, A. Ilg, J. Holz, and G. N. Duda, performed at Charité University Hospital, Berlin, Germany, in collaboration with OrthoCentrum Hamburg and Zuse Institute Berlin, has been accepted for publication in the peer-reviewed scientific journal Knee Surgery, Sports Traumatology, Arthroscopy (KSSTA). The objective of this retrospective study was to measure the knee function of patients who received an Episealer® knee implant and compare with the knee function of patients who received a total knee prosthesis as well as with patients with healthy, untreated knees. The study concludes that the knee functionality for patients treated with an Episealer® implant is essentially in line with untreated knees, and significantly better than for patients treated with total knee replacements. The publication is expected to be available online shortly.

The Episealer® Knee implant is intended for treatment of focal cartilage and osteochondral defects on the femoral side of the knee joint. The Episealer® Knee implant is fully tailored to fit each patient’s unique curvature of the joint surface, the size and shape of the lesion, and underlying bone conditions.

”This study shows, as expected in connection with a patient-specific implant, that the Episealer® knees move in an almost normal fashion and distinctly different from TKA knees. Translated into clinical terms, this means that Episealer® knees may have normal knee function”, says Prof. Leif Ryd, Senior Medical Advisor, Episurf Medical.

This is the first comparative study with patients who have received Episealer® implants. We are pleased to hear that the results are in line with our expectations and that we actually restore the joint function. We are looking forward to reading the full publication, however, there is no doubt about the fact that this adds a great deal of value to a growing, and now a quite sizeable, collection of strong clinical evidence in favour of our technology”, says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.45 CEST on 10 September 2021.

Tags: